Skip to content
Oncology Research Hub

Iowa

Cancer clinical trials in Iowa

153 cancer studies are recruiting participants at sites in 18 cities across Iowa as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Iowa city with a recruiting study

By research area: Lymphoma (45), Breast Cancer (37), Lung Cancer (37), Prostate Cancer (16), Pancreatic Cancer (10), Melanoma (8).

Iowa City (91), Des Moines (62), Waukee (48), Clive (38), Ankeny (37), Cedar Rapids (37), Ames (35), Fort Dodge (31), Marshalltown (28), West Des Moines (16), Carroll (15), Bettendorf (9), Creston (8), Council Bluffs (6), Pella (6), Waterloo (5), Boone (4), Jefferson (4).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Iowa

Basic details from each study's public record (the 12 most recently updated of 153). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Recruiting in
    Iowa City
    Registry record
    NCT06324357 · updated
  2. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Recruiting in
    Clive · Des Moines · West Des Moines
    Registry record
    NCT03418961 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Iowa on ClinicalTrials.gov.

Prostate cancer: recently updated in Iowa

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Cedar Rapids
    Registry record
    NCT04423211 · updated
  2. TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

    • Phase 1/2
    • Ages 18 and older
    • Male participants
    Sponsor
    Novartis Pharmaceuticals
    Recruiting in
    Iowa City
    Registry record
    NCT07190300 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Iowa on ClinicalTrials.gov.

Lymphoma: recently updated in Iowa

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Recruiting in
    Iowa City
    Registry record
    NCT06724237 · updated
  2. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Waukee
    Registry record
    NCT06806033 · updated
  3. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Recruiting in
    Iowa City
    Registry record
    NCT07221500 · updated
  4. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Iowa City · Waukee
    Registry record
    NCT06890884 · updated
  5. Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    AstraZeneca
    Recruiting in
    Iowa City
    Registry record
    NCT07109219 · updated
  6. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Ankeny · Clive · Des Moines · and 1 more U.S. location
    Registry record
    NCT03739814 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Iowa on ClinicalTrials.gov.

Ask about studies in Iowa

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call